Published in Blood on August 15, 1994
Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A (2006) 2.01
Relipidated tissue factor linked to collagen surfaces potentiates platelet adhesion and fibrin formation in a microfluidic model of vessel injury. Bioconjug Chem (2011) 1.08
Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci U S A (2012) 0.97
Fluid shear stress alters the hemostatic properties of endothelial outgrowth cells. Tissue Eng Part A (2011) 0.93
Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombin. Biochem J (1996) 0.85
Human coagulation factor VIII domain-specific recombinant polypeptide expression. Blood Res (2015) 0.75
Cloning and comparison of factor X from rhesus monkey (Macaca mulatta). Comp Med (2009) 0.75
Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature (1979) 3.06
CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem (1991) 2.82
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res (2000) 2.37
Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature (1986) 2.31
Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol (1972) 2.30
A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A (1997) 2.22
Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood (2000) 2.12
Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med (1995) 1.93
Multivesicular bodies are an intermediate stage in the formation of platelet alpha-granules. Blood (1998) 1.88
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem (1977) 1.86
Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest (1978) 1.66
von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood (1999) 1.62
Structure-function relationship of human von Willebrand factor. Blood (1987) 1.60
Blood platelets are concentrated near the wall and red blood cells, in the center in flowing blood. Arteriosclerosis (1989) 1.57
Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation (1999) 1.54
Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke (1993) 1.54
Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci U S A (1977) 1.52
Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost (2003) 1.52
Concordance of phenprocoumon dosage in married couples. BMJ (1997) 1.51
Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood (1995) 1.50
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost (2000) 1.49
Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation (2000) 1.45
A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med (1983) 1.44
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost (2000) 1.43
C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa. Thromb Haemost (2001) 1.40
Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. J Clin Invest (1985) 1.40
[Thrombotic thrombocytopenic purpura: a benign disease with a very severe acute phase]. Ned Tijdschr Geneeskd (1990) 1.39
The role of collagen in thrombosis and hemostasis. J Thromb Haemost (2004) 1.38
Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost (2007) 1.38
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost (2000) 1.32
The hemostatic plug. Semin Hematol (1977) 1.31
Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med (1978) 1.30
Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med (1981) 1.29
Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem (1994) 1.27
Inactivation of kallikrein in human plasma. J Clin Invest (1983) 1.27
Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med (1978) 1.26
Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res (1974) 1.26
Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost (2001) 1.26
The origin of P-selectin as a circulating plasma protein. Thromb Haemost (1997) 1.25
Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest (1994) 1.23
A new method to study shape recovery of red blood cells using multiple optical trapping. Biophys J (1995) 1.23
Red blood cell size is important for adherence of blood platelets to artery subendothelium. Blood (1983) 1.23
Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest (1997) 1.23
Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood (1994) 1.21
Chorea in systemic lupus erythematosus and "lupus-like" disease: association with antiphospholipid antibodies. Semin Arthritis Rheum (1987) 1.21
Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest (1998) 1.21
Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding. Structure (1997) 1.20
The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol (1986) 1.20
Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood (1986) 1.20
Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood (1987) 1.18
Platelet and fibrin deposition at the damaged vessel wall: cooperative substrates for neutrophil adhesion under flow conditions. Blood (1997) 1.17
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood (1995) 1.16
Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum (1986) 1.15
Structural studies on the O-linked carbohydrate chains of human platelet glycocalicin. Eur J Biochem (1984) 1.14
Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost (1988) 1.14
Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood (1997) 1.12
Subendothelial proteins and platelet adhesion. von Willebrand factor and fibronectin, not thrombospondin, are involved in platelet adhesion to extracellular matrix of human vascular endothelial cells. Arteriosclerosis (1986) 1.12
Thrombin stimulates glucose transport in human platelets via the translocation of the glucose transporter GLUT-3 from alpha-granules to the cell surface. J Cell Biol (1997) 1.12
Hemostasis in menstrual endometrium: a review. Obstet Gynecol Surv (1982) 1.11
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology (2001) 1.11
Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke (1997) 1.11
Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis (1983) 1.10
Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur J Biochem (1987) 1.10
DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood (1984) 1.10
Von Willebrand factor in the vessel wall mediates platelet adherence. Blood (1985) 1.09
Thrombosis and hemostasis in renal disease. Kidney Int (1994) 1.09
Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry (1980) 1.08
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis (1985) 1.07
Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation (1992) 1.07
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet (1999) 1.07
Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood (1991) 1.07
Kinetics of intravenously administered heparin in normal humans. Blood (1982) 1.06
Identification of the collagen-binding site of the von Willebrand factor A3-domain. J Biol Chem (2000) 1.06
Immunocytochemical localization of fibrinogen, platelet factor 4, and beta thromboglobulin in thin frozen sections of human blood platelets. J Clin Invest (1983) 1.05
Fibronectin in artery subendothelium is important for platelet adhesion. Blood (1985) 1.04
Adenine nucleotide metabolism of blood platelets. 8. Transport of adenine into human platelets. Biochim Biophys Acta (1973) 1.04
Isolation and functional characterization of the active light chain of activated human blood coagulation factor XI. J Biol Chem (1983) 1.04
Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deficiency: a study of 125 patients of several ethnic backgrounds. J Lab Clin Med (1985) 1.04
A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost (1996) 1.04
Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost (1998) 1.03
Purified protein S contains multimeric forms with increased APC-independent anticoagulant activity. Biochemistry (2001) 1.03
Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med (1981) 1.02
Red blood cell deformability influences platelets--vessel wall interaction in flowing blood. Blood (1984) 1.02
Immunocytochemical localization of albumin and factor XIII in thin cryo sections of human blood platelets. Thromb Haemost (1984) 1.01
Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood (1984) 1.01
Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest (1988) 1.01
Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost (2002) 1.00